Endocyte Inc. (NASDAQ:ECYT) shares traded up 2.9% during trading on Wednesday . The stock traded as high as $3.26 and last traded at $3.22, with a volume of 129,247 shares. The stock had previously closed at $3.13.

Several research analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Endocyte in a report on Wednesday, May 4th. Zacks Investment Research downgraded Endocyte from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Cowen and Company reiterated a “buy” rating on shares of Endocyte in a report on Wednesday, May 4th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Endocyte in a research note on Tuesday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $11.15.

The stock has a 50 day moving average of $3.48 and a 200-day moving average of $3.44. The firm’s market cap is $135.73 million.

Endocyte (NASDAQ:ECYT) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the company posted ($0.26) EPS. Equities analysts predict that Endocyte Inc. will post ($1.10) EPS for the current fiscal year.

In related news, insider Philip S. Low acquired 11,375 shares of the company’s stock in a transaction on Tuesday, May 10th. The stock was acquired at an average price of $3.52 per share, with a total value of $40,040.00. Following the acquisition, the insider now directly owns 206,606 shares of the company’s stock, valued at $727,253.12. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.